Calmare Therapeutics — Shareholder Meeting (November 2016)
31 slides from Calmare Therapeutics's shareholder meeting presentation, Nov 21, 2016
Slide 1: Annual General Meeting of Shareholders
CALMARE “THERAPEUTICS ANNUAL GENERAL MEETING OF SHAREHOLDERS Putting the puzzle pieces together ... Zi.
Slide 2: Safe Harbor Disclosure
CALMARE Safe Harbor Disclosure ——— THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS,
Slide 3: Question
= QUESTION
Slide 4: What has management been doing the past months?
What has management been doing the past 13 months?
Slide 5: Putting the puzzle pieces together to make an industry powerhouse
Putting the puzzle pieces together to make an industry powerhouse
Slide 6: Four pieces of success
EF cAimare THERAPEUTICS Four pieces of success ... a. Company: CTTC b. Industry: Medical Devices c. Brand: Calmare d. Plan: Devices, Patient Treatment ‘ozmcamae Magnes toning
Slide 7: Company
ECAIMARE *~ THERAPEUTICS Company ng ‘0201scamae Magan Heong
Slide 8: We had parts of a former company
(ECALMARE = We HAD parts of a former company: + IP portfolio with dying business model A decimated stock price of $ .05 Problems with our government contract Comprehensive litigations No viable business plan ‘0201scamae Magan Heong
Slide 9: We made
CALMARE ay | We MADE: A medical device company whose medical products and modalities treats chronic pain without need of drugs A $15 million Blanket Purchase Agreement that relates into $250,000 per month for 60 months starting in the first quarter of 2017 A team of professionals that have medical,
Slide 10: Industry: Medical Devices
EF cAimare THERAPEUTICS Industry: Medical Devices ‘0201scamae Magan Heong
Slide 11: $5.1 billion global neurostimulation devices market
[2] $ 5.1 billion Global neurostimulation devices market ~ CAGR of 12.7% between 2014 and 2020 ~
Slide 12: But why chronic pain?
EF cAimare THERAPEUTICS But why chronic pain?
Slide 13: U.S. adults in chronic pain daily
116 million U.S. adults in chronic pain daily ~ American Academy of Pain Medicine. 2015~
Slide 14: Today's solution is a problem
Today’s solution is a problem
Slide 15: Number of Deaths from Prescription Opioid Pain Relievers
Number of Deaths from Prescription Opioid Pain Relievers * 20,000 USA ™ Total “=~ Female = Male 18,000 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 ‘ SEEFLELIIISES SSS Sab eS ‘ozmcamae Magnes toning
Slide 16: People die every day from opioid prescription painkillers
[«] 45 people die every day from opioid prescription painkillers — more deaths than heroin and cocaine overdose combined ~ National Survey on Drug Use and Health. 2015 ~
Slide 17: There is another solution
... there is another solution
Slide 18: The Calmare Pain Therapy Device
if CALMARE Ears, we. The Calmare® Pain Therapy Device = U.S. FDA 510(k) clearance: #K081255 = CE-marking: European sales = G.S.A. Contractor: - \V797P-4300B - VA-119-15-Q-0496
Slide 19: Calmare Pain Mitigation Therapy
CALMARE Calmare Pain Mitigation Therapy™ The only non-invasive, non-addictive, non-drug pain therapy that offers prolonged chronic pain relief.
Slide 20: Brand: Calmare
if CALMARE THERAPEUTICS Brand: @CALMAR E
Slide 21: The Calmare Pain Family
(AE CALMARE THERAPEUTICS de fa The Calmare® Pain Family Products Calmare® Pain Therapy Device Calmare Cart Calmare Sample Pack
Slide 22: The Plan: Device Sales and Patient Treatments
CALMARE *~ RAPEUTICS The Plan: Device Sales and Patient Treatments ‘0201scamae Magan Heong
Slide 23: U.S. Government Sales Contracts
Coane U.S. Government Sales Contracts: 1) General Services Administration (V797P-4300B | Calmare Devices) (4/10) 2) Unsolicited Bid: $2.5 million (est.) Calmare PMT Trial (IN PROCESS) ¥ Diagnosis: Lower Back Surgery Syndrome ¥ Endpoint: 10% pain intensity improvement v Devices: 20 3) General Supply
Slide 24: Global Commercial Sales
ECAare “x PP» Global Commercial Sales ~ United States: * FDA “Clearance” + private practices * hospitals with specialized medical practices. Overseas: * licensed and accredited medical physicians, and hospitals * Ministry of Health departments that honor the Calmare Pain Therapy Device’s U.S. FDA 51
Slide 25: Centers of Excellence
ECAIMARE a THERAPEUTICS Centers of Excellence Patient treatment business — CPMT licensure and training — Local distribution hub — Continued education ‘ozmcamae Magnes toning
Slide 26: Management Team
Management Team ——— Conrad Mir, Director, President & CEO y He the Board of Directors Most recently, cm, of Pressure oscencas nc, (OTCOB: Palo) 8 Before that, and CEO of ‘a plasmid, DNA. space, ‘of Advaxis, Inc. (NASDAQ: ADXS), a vaccine company. Over the Tast ve L pseliehsoeiee salpreeierrac aokier
Slide 27: Medical Team
Medical Team ———— Dr. Stephen D'Amato, MD, FACEP, Dr. D’Amato he Rhode over 1000 patents treated in his mica spate Pox ering alma ie waa he medical director and staff here, he was a Clinical Asitnt Professor edi Prowidonce, Ri He has boon part of he mesial staf of St loseph Hospia's Fatma Unit and M
Slide 28: Board of Directors
‘CALMARE - EC AMARE Board of Directors a Pe |. Poter brings finn rites logy companies. He was the Now York Society 1 Ch sr, US Navy. Retire, Pe F in 1972 Fis worldwide servic inches Joint and Nay positons overseas and in both esol (00 878), USS Towers (00G 8). USS Barri (CGN 29, a USS Grey C521) You
Slide 29: Board of Directors
CALMARE Hi nce Board of Directors a Cad 'Connet, CEO for kor Spine, and ialnelogy, ENT and Dentist, Fis ‘Ophihalmogy, ENT. and Denis. forthe nd CE Technologies. He from Moun St Marys Colege, Maryand, US Navy, Retired, light manuf Porto READY ROOM. lohson & “There, t Before JNJ Prior private sector,
Slide 30: We are the missing piece that improves the quality of life in chronic pain sufferers
We are the missing piece that improves the quality of life in chronic pain sufferers.
Slide 31: Go Calmare Therapeutics
GO CALMARE 7 THERAPEUTICS Conrad Mir President & CEO +1 973.876.1774 Sf arte, you! [email protected] ‘www.calmaretherapeutics.com www.calmarett.com OTC:CTTC ‘o2mcamae Magan torte
Calmare Therapeutics — Shareholder Meeting (November 2016) on 6ix